Aliskiren for Immunoglobulin A (IgA) Nephropathy

Status Completed

Clinical Trial Summary

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. Current treatment with angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) is not entirely effective. Aliskiren, a direct renin inhibitor, acts on the rate limiting step of the renin-angiotensin axis. In addition to lowering the blood pressure, recent study in diabetic nephropathy suggests an independent anti-proteinuric effect. The investigators plan to conduct a randomized placebo-control cross-over study to evaluate the safety and efficacy of aliskiren in the treatment of IgA nephropathy. The investigators plan to recruit 57 patients with biopsy-proven IgA nephropathy and persistent proteinuria despite conventional therapy. They will be randomized to aliskiren for 16 weeks or no treatment, followed by cross over to the other arm after a washout period. Proteinuria, albuminuria, renal function, serum and urinary markers will be quantified. This study will explore the potential anti-proteinuric effect of aliskiren in the treatment of IgA nephropathy, which has no specific treatment at present.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00870493
Study type	Interventional
Source	Chinese University of Hong Kong
Contact
Status	Completed
Phase	Phase 3
Start date	April 2009
Completion date	July 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05016323` - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.	Phase 2
Withdrawn	`NCT02433236` - Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy	Phase 2
Recruiting	`NCT02231125` - Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy	Phase 4
Completed	`NCT01502579` - An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data	N/A
Not yet recruiting	`NCT01203007` - Diet Intervention in Food Sensitive Patients With IgA Nephropathy	N/A
Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
Completed	`NCT00657059` - Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)	Phase 3
Recruiting	`NCT04684745` - Open-Label Extension Study of BION-1301 in IgA Nephropathy	Phase 2
Completed	`NCT03719443` - First in Human Study to Assess Safety of VIS649 in Healthy Subjects	Phase 1
Completed	`NCT02112838` - Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy	Phase 2
Withdrawn	`NCT02052219` - BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy	Phase 3
Completed	`NCT00767221` - Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study	Phase 2
Recruiting	`NCT04438603` - The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Terminated	`NCT04905212` - A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy	Phase 2
Terminated	`NCT04042623` - Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy	Phase 2
Recruiting	`NCT03633864` - Fecal Microbiota Transplantation for Refractory IgA Nephropathy	Phase 2
Not yet recruiting	`NCT06454110` - Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)	Phase 2
Recruiting	`NCT02954419` - IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Recruiting	`NCT03001947` - IgA Nephropathy Registration Initiative of High Quality (INSIGHT)